Technically we develop medicines. Practically we improve conditions for patients.

Ferring's R&D activities are always driven by the same goals: to develop patient-friendly products that treat unmet medical needs in our key therapeutic areas. We focus our R&D efforts on peptide-based drugs and biotechnology derived medicines.
Later stage small chemical molecules within our core therapeutic areas are also included in our development portfolio.
Investment in development includes the incorporation of state-of-the-art technology to capitalise on the company’s expertise.
We also strive to develop drug delivery systems that ensure convenient and efficient administration of our drugs.

  • Reproductive Health
    Reproductive Health

  • Reproductive Health

    Ferring is a world leader in Assisted Reproductive Technology (ART) for fertility treatment. Ferring’s on-going research efforts in this area strive to meet the growing needs of patients as increasing numbers of couples seek help to conceive. Ferring also offers a range of peptide-based medicines in obstetric care - labour induction, and to prevent preterm birth and postpartum haemorrhage.

     

  • Urology
    Urology

  • Urology

    Ferring is committed to the development of medicines to treat urological disorders such as diabetes insipidus, enuresis and nocturia.

    Prostate cancer is another disease area where Ferring also actively engages in. We are conducting clinical studies to further demonstrate the benefits of therapy using (GnRH) receptor antagonist monthly depot in the management of advanced prostate cancer.

  • Gastroenterology
    Gastroenterology

  • Gastroenterology

    Ferring has a strong heritage of educational support, sponsorship and clinical research within Inflammatory Bowel Disease (IBD). A series of developmental initiatives are underway to bring new products in this indication to market. Recently, Ferring has also launched colonic-release oral corticosteroid.

    The Ferring gastroenterology portfolio also includes bowel preparation (to prepare patients for colonoscopy) and the pharmacological treatment for complications resulting from end-stage liver cirrhosis.

  • Endocrinology
    Endocrinology

  • Endocrinology

    Ferring has peptide-based medicines targeting pituitary malfunctioning which causes growth failure in children.

     

  • Orthopaedics
    Orthopaedics

  • Orthopaedics

    Ferring has recently started the development in the orthopaedic area to help knee osteoarthritis sufferers to reduce pain.

Ferring Hong Kong

FERRING PHARMACEUTICALS LTD.
SUITES 2604-05, 26/F.,
AXA TOWER, LANDMARK EAST,
100 HOW MING STREET,
KWUN TONG, KOWLOON,
HONG KONG

Tel: (852) 2622 8020
Fax: (852) 2622 8001